Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
Lipocine Inc. (NASDAQ: LPCN) is set to host a virtual key opinion leader (KOL) event on October 16, 2024 at 11:00 am ET, focusing on LPCN 2401 for improved body composition in obesity management. The event will feature Dr. Frank Greenway, Professor and Chief Medical Officer at Pennington Biomedical Research Center, who will discuss unmet needs and current treatments in obesity management, emphasizing fat loss and lean muscle mass preservation for patients on incretin therapies.
The presentation will also cover positive data from the Phase 2 study of LPCN 2401, an oral proprietary androgen receptor agonist. The study showed significant improvements in body composition, suggesting potential use as an adjunct with incretin mimetics (GLP-1/GIP agonists) or as a monotherapy, including post incretin mimetic discontinuation. A live Q&A session will follow the formal presentation.
Lipocine Inc. (NASDAQ: LPCN) ospiterà un evento virtuale con esperti di opinione (KOL) il 16 ottobre 2024 alle 11:00 ET, concentrandosi su LPCN 2401 per migliorare la composizione corporea nella gestione dell'obesità. L'evento vedrà la partecipazione del Dr. Frank Greenway, Professore e Chief Medical Officer presso il Pennington Biomedical Research Center, che discuterà i bisogni insoddisfatti e i trattamenti attuali nella gestione dell'obesità, enfatizzando la perdita di grasso e il mantenimento della massa muscolare magra per i pazienti in terapia con incretine.
La presentazione coprirà anche dati positivi dello studio di Fase 2 di LPCN 2401, un agonista recettore androgeno orale proprietario. Lo studio ha mostrato significativi miglioramenti nella composizione corporea, suggerendo un uso potenziale come trattamento adiuvante con mimetici delle incretine (agonisti GLP-1/GIP) o come terapia monofarmaco, incluso dopo l'interruzione dei mimetici delle incretine. Una sessione di domande e risposte dal vivo seguirà la presentazione formale.
Lipocine Inc. (NASDAQ: LPCN) organizará un evento virtual con líderes de opinión (KOL) el 16 de octubre de 2024 a las 11:00 a.m. ET, centrado en LPCN 2401 para mejorar la composición corporal en el manejo de la obesidad. El evento contará con la participación del Dr. Frank Greenway, Profesor y Director Médico en el Pennington Biomedical Research Center, quien discutirá las necesidades no satisfechas y los tratamientos actuales en el manejo de la obesidad, enfatizando la pérdida de grasa y la preservación de la masa muscular magra para los pacientes en terapias con incretinas.
La presentación también cubrirá datos positivos del estudio de Fase 2 de LPCN 2401, un agonista de receptor androgénico oral propietario. El estudio mostró mejoras significativas en la composición corporal, sugiriendo un uso potencial como un complemento con miméticos de incretina (agonistas GLP-1/GIP) o como una monoterapia, incluyendo después de la discontinuación del mimético de incretina. Una sesión de preguntas y respuestas en vivo seguirá a la presentación formal.
리포신 Inc. (NASDAQ: LPCN)는 2024년 10월 16일 오전 11시 ET에 비만 관리에서 신체 구성 개선을 위한 LPCN 2401에 초점을 맞춘 가상 키 오피니언 리더(KOL) 이벤트를 개최할 예정입니다. 이 이벤트에는 프랭크 그린웨이 박사, 펜nington 생의학 연구 센터의 교수 및 최고 의료 책임자가 참석하여 비만 관리의 충족되지 않은 필요와 현재 치료법에 대해 논의할 예정이며, 인크레틴 요법을 받는 환자들을 위한 지방 손실 및 제지방 근육량 보존을 강조할 것입니다.
발표에서는 또한 구두 전용 안드로겐 수용체 작용제인 LPCN 2401의 2상 연구 결과에 대한 긍정적인 데이터도 다룰 것입니다. 이 연구는 신체 구성의 유의미한 개선을 보여주었으며, 인크레틴 유사체(GLP-1/GIP 작용제)와 함께 보조 요법으로 사용될 가능성이나 인크레틴 유사체 사용 중단 후 단독 요법으로 사용할 가능성을 제시합니다. 공식 발표 후에는 라이브 Q&A 세션이 진행됩니다.
Lipocine Inc. (NASDAQ: LPCN) organisera un événement virtuel avec des leaders d'opinion (KOL) le 16 octobre 2024 à 11h00 ET, axé sur LPCN 2401 pour améliorer la composition corporelle dans la gestion de l'obésité. L'événement présentera Dr. Frank Greenway, Professeur et Directeur Médical au Pennington Biomedical Research Center, qui discutera des besoins non satisfaits et des traitements actuels en matière de gestion de l'obésité, mettant l'accent sur la perte de graisse et la préservation de la masse musculaire maigre pour les patients sous thérapies incrétinées.
La présentation abordera également des données positives de l'étude de Phase 2 de LPCN 2401, un agoniste des récepteurs androgéniques oral propriétaire. L'étude a montré des améliorations significatives de la composition corporelle, suggérant un usage potentiel comme traitement adjuvant avec des mimétiques de l'incrétine (agonistes GLP-1/GIP) ou comme monothérapie, y compris après l'arrêt du mimétique de l'incrétine. Une session de questions-réponses en direct suivra la présentation formelle.
Lipocine Inc. (NASDAQ: LPCN) wird am 16. Oktober 2024 um 11:00 Uhr ET ein virtuelles Event mit Meinungsführern (KOL) veranstalten, das sich auf LPCN 2401 zur Verbesserung der Körperzusammensetzung im Rahmen des Adipositas-Managements konzentriert. Die Veranstaltung wird Dr. Frank Greenway, Professor und Chief Medical Officer am Pennington Biomedical Research Center, umfassen, der unerfüllte Bedürfnisse und aktuelle Behandlungen im Adipositas-Management besprechen wird, wobei der Schwerpunkt auf Fettabbau und Erhaltung der fettfreien Muskelmasse bei Patienten unter Incretintherapien gelegt wird.
Die Präsentation wird auch positive Daten aus der Phase-2-Studie zu LPCN 2401, einem oral verfügbaren, proprietären Androgenrezeptor-Agonisten, behandeln. Die Studie zeigte erhebliche Verbesserungen der Körperzusammensetzung und deutet auf eine mögliche Verwendung als Zusatztherapie neben Incretin-Mimetika (GLP-1/GIP-Agonisten) oder als Monotherapie hin, einschließlich nach dem Absetzen des Incretin-Mimetikums. Eine Live-Q&A-Sitzung wird auf die formelle Präsentation folgen.
- None.
- None.
The event will feature Frank Greenway, MD (Professor and Chief Medical Officer at Pennington Biomedical Research Center), who will discuss the unmet needs and current treatment landscape in obesity management with a focus on fat loss and lean muscle mass preservation for patients on incretin therapies.
The event will also review positive data from the Phase 2 study of LPCN 2401, comprised of an oral proprietary androgen receptor agonist, which showed significant improvements in body composition. The data support the potential for LPCN 2401 to be used as an adjunct with incretin mimetics (GLP-1/GIP agonists) or as a monotherapy, including post incretin mimetic discontinuation.
A live question and answer session will follow the formal presentation.
About LPCN 2401
LPCN 2401 is an oral formulation comprised of a proprietary anabolic androgen receptor agonist targeted for once daily regimen. Data from preclinical and clinical studies support the potential of LPCN 2401 in preserving lean mass while reducing fat mass (preferentially VAT and android fat) and beneficial liver and bone health effects. As adjunct therapy to incretin mimetics, LPCN 2401 has potential to amplify GLP-1 action, ameliorate loss of muscle mass, improve muscle quality and functionality, and amplify fat mass loss with improved body composition, with no overlapping GI side effects. Moreover, post incretin mimetic discontinuation, LPCN 2401 has potential to attenuate weight gain, prevent "fat overshoot," and accelerate lean mass rebound.
About Lipocine
Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.
Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression; LPCN 2101, for the potential treatment of epilepsy; LPCN 2203, an oral candidate targeted for the management of essential tremor; LPCN 2401, comprised of an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics as an aid for improved body composition in chronic weight management; and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for chronic weight management, LPCN 1148 for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.
Forward-Looking Statements
This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products, our ability to monetize product candidates, including through entering into partnering arrangements, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-to-host-virtual-kol-event-on-lpcn-2401-for-improved-body-composition-in-obesity-management-on-october-16-2024-302264702.html
SOURCE Lipocine Inc.
FAQ
When is Lipocine's virtual KOL event on LPCN 2401 scheduled?
What is the focus of Lipocine's upcoming KOL event for LPCN 2401?
Who is the key opinion leader speaking at Lipocine's LPCN 2401 event?
What were the results of the Phase 2 study for LPCN 2401?
How can LPCN 2401 be used in obesity management according to the Phase 2 study?
